Just a moment...
We've upgraded AI Search on TaxTMI with two powerful modes:
1. Basic
• Quick overview summary answering your query with references
• Category-wise results to explore all relevant documents on TaxTMI
2. Advanced
• Includes everything in Basic
• Detailed report covering:
- Overview Summary
- Governing Provisions [Acts, Notifications, Circulars]
- Relevant Case Laws
- Tariff / Classification / HSN
- Expert views from TaxTMI
- Practical Guidance with immediate steps and dispute strategy
• Also highlights how each document is relevant to your query, helping you quickly understand key insights without reading the full text.
Help Us Improve - by giving the rating with each AI Result:
Powered by Weblekha - Building Scalable Websites
Press 'Enter' to add multiple search terms. Rules for Better Search
Press 'Enter' after typing page number.
Press 'Enter' after typing page number.
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
Press 'Enter' after typing page number.
Press 'Enter' after typing page number.
Don't have an account? Register Here
Press 'Enter' after typing page number.
<h1>Varicella vaccine NEXIPOX PLUS launched with trehalose stabiliser, 98% seroconversion, and regulatory approval from 12 months.</h1> NEXIPOX PLUS is a reformulated live attenuated varicella vaccine using a 2X trehalose stabiliser to enhance viral stability, preserve potency, reduce antigen crystallisation and lower allergic-reaction risk. Clinical data report 98% seroconversion after a two-dose schedule and a 35.4-fold geometric mean rise in antibody titres, with no serious adverse events causally linked to the vaccine and improved tolerability following removal of gelatin. The product is approved by the Drugs Controller General of India for use from 12 months of age and is protected by patents across 156 countries.